New CMS Demo Aims to Increase Access to GLP-1s Under Medicaid and Part D

(MedPage Today) — The Trump administration announced a new demonstration program aimed at easing access to GLP-1 receptor agonists for enrollees in Medicare Part D and Medicaid plans, but experts say it’s unclear how popular or effective it will…

Source link : https://www.medpagetoday.com/publichealthpolicy/washington-watch/119239

Author :

Publish date : 2025-12-31 18:28:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

New CMS Demo Aims to Increase Access to GLP-1s Under Medicaid and Part D

What’s the Time Burden of Women’s Cancers-Related Tasks?

Related Posts

What’s the Time Burden of Women’s Cancers-Related Tasks?

ADHD Drugs Work Differently? Infant Screen Time; GLP-1 Psychological Side Effects

Real-World Outcomes With Bispecifics in Relapsed/Refractory Large B-Cell Lymphoma

Pre-Existing Fatigue Tied to Worse Toxicity From Systemic Cancer Therapy

Common Chemicals Tied to Increased MS Risk

Salt and Skin: Could Sodium Be Fueling Psoriasis and Atopic Dermatitis?

New CMS Demo Aims to Increase Access to GLP-1s Under Medicaid and Part D

What’s the Time Burden of Women’s Cancers-Related Tasks?

ADHD Drugs Work Differently? Infant Screen Time; GLP-1 Psychological Side Effects

Real-World Outcomes With Bispecifics in Relapsed/Refractory Large B-Cell Lymphoma

Pre-Existing Fatigue Tied to Worse Toxicity From Systemic Cancer Therapy

Common Chemicals Tied to Increased MS Risk

Salt and Skin: Could Sodium Be Fueling Psoriasis and Atopic Dermatitis?

DOJ Sent Letters to Medical Journals. Then What Happened?

Categories

Archives